To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorPeking University People's Hospital

About this trial

This project aims to innovatively integrate multi-omics data, including plasma metabolomics, radiomics, and cfDNA multi-level information, combined with survival data (e.g., RFS), to establish a novel multidimensional approach for noninvasive postoperative recurrence monitoring in lung cancer using artificial intelligence algorithms. The goal is to develop a new noninvasive recurrence monitoring system for lung cancer.

Eligibility criteria

Qualifiers

Signed written informed consent.

Male or female, aged ≥ 18 and < 85 years.

Radical resection performed, pathologic stage IB-IIIA (8th TNM) non-small-cell lung cancer.

Tumor tissue and blood samples obtainable at all protocol-specified time-points.

Disqualifiers

Postoperative pathology shows other than NSCLC, including but not limited to benign lesions, small-cell carcinoma, metastasis, or indeterminate/inadequate histology.

Insufficient or poor-quality blood or tissue samples.

Pure ground-glass nodule on imaging.

History of any malignancy within the past 5 years.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

100 Participants
are grouped into 2 trial groups